BPC 157 Reverses Liver Scarring and High Liver Blood Pressure in Rats with Bile Duct Disease

Bile duct ligation (BDL) in rats to induce liver fibrosis and portal hypertension. BPC 157 was administered via three routes: continuously in drinking water, by intraperitoneal injection (starting 30 minutes post-surgery or at week 4), or by local bath application. Rats were sacrificed at 2, 4, 6, and 8 weeks. Outcomes included gross pathology, histology (necrosis, fibrosis, stellate cell activation via α-SMA, collagen via Mallory stain, proliferation via Ki-67), serum liver function tests, tissue oxidative stress and nitric oxide markers, NOS2/NOS3 Western blots, and inflammatory cytokine levels.

Liver fibrosis and portal hypertension are major causes of death in chronic liver disease, and current treatments are limited. BPC 157 showed remarkably comprehensive effects in this model — addressing fibrosis, inflammation, cell death, portal pressure, and liver function simultaneously. While this is an animal study, the breadth of effects across multiple outcome measures and the dose-response at very low concentrations make it a notable preclinical finding in the BPC 157 research literature.

Liver fibrosis affects hundreds of millions of people worldwide (from alcohol, obesity-related NAFLD, and viral hepatitis) and can progress to cirrhosis and death. There are very few drugs that can reverse established fibrosis. BPC 157's apparent ability to reverse fibrosis, reduce portal hypertension, and restore liver function across multiple outcome measures makes it one of the more intriguing preclinical candidates — but the field desperately needs independent replication and human trials to determine if these dramatic animal results translate to clinical medicine.

All results are from rats — no human liver fibrosis data exists for BPC 157. The bile duct ligation model causes obstructive liver disease, which differs from the most common human causes of fibrosis (alcohol, NAFLD, viral hepatitis). The study comes from the Sikiric group in Zagreb, which produces the vast majority of BPC 157 research — independent replication by other groups is limited. The breadth of claimed effects (fibrosis, necrosis, inflammation, portal hypertension, liver function, oxidative stress all reversed) is extraordinary for a single peptide and warrants independent validation.